Blue Longevity raises €2m for clinic rollout
Blue Longevity Clinic has raised €2m to expand its longevity medicine clinics in Bulgaria, Greece and Turkey, supported by proprietary diagnostic protocols and digital tools.
The Sofia-based healthtech provider plans to open centres in Sofia, Athens and Istanbul in September this year, offering services aimed at extending healthspan — the number of years lived in good health — through personalised diagnostics and therapies.
Founded in 2024 by Ilian Grigorov (City Clinic, Blocks Health), Blagoy Palev (former banker and co-founder of Blocks Health) and Dr George Vissarakis (former director at Filoktitis Center, Greece), the company combines in-person functional diagnostics with digital health tracking and an app designed to encourage healthy lifestyle changes through microhabit formation.
Grigorov said: “We’re building a new kind of health centre – one that people don’t just visit once a year, but one that becomes part of their lifestyle,.
“Longevity is not a single test or therapy – it’s a journey.
“Our goal is to be the first truly integrated and accessible preventive health platform in the region and one of the global leaders in providing longevity medicine services.”
The vertically integrated model aims to bridge the current market gap between diagnostic-only or non-personalised longevity clinics.
Its approach identifies early signs of deviation from optimal function before disease develops. Assessments cover metabolic health, brain function, gut microbiome and genetic risk — all of which influence how the body ages.
Each client receives a physician-led health optimisation plan that may include in-house therapies such as hyperbaric oxygen therapy (breathing pure oxygen in a pressurised chamber), cryotherapy (exposure to cold temperatures) and red light therapy (targeted light wavelengths used to promote healing).
The funding round was led by Eleven Ventures, with participation from Sofia Angels Ventures and several family offices.
The investment will support clinical build-outs, finalisation of the therapy protocol stack, expansion of the medical team, and scaling of the proprietary technology platform.
Valeri Petrov, partner at Eleven Ventures, said: “The transition from reactive sick care to proactive health care is no longer a trend, it’s a global shift.
“We’ve been closely tracking this category and believe the SEE region has the potential to become a key hub for medical and longevity tourism.
“Blue Longevity is one of the first companies locally to combine medical credibility, product depth, and entrepreneurial experience into a scalable model.”
The company said access to advanced diagnostics and longevity therapies has largely remained limited to high-net-worth individuals through exclusive clinics.
Southeastern Europe has been slower to adopt such innovations, particularly as they fall outside the focus of traditional hospitals.
Blue Longevity aims to bring these services to the emerging upper-middle class in the region, which the company notes has one of the highest out-of-pocket health spending levels in Europe.
